AprilBio
에이프릴바이오 · 397030
Health Care Biotechnology · KOSDAQ
Market cap US$972.2M (₩1.3T)
Overview
AprilBio develops antibody-based medicines and long-acting protein drugs, biological therapies designed to treat autoimmune, inflammatory, cancer, and rare diseases.
It is a research-stage biotech listed on KOSDAQ, Korea's tech-focused stock exchange, that advances drug candidates through early clinical stages and then licenses them to larger pharmaceutical partners worldwide. Its core business model, which it calls RIPCO, is to earn revenue through upfront payments, milestone fees, and royalties from these technology-licensing deals rather than commercializing drugs itself.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$0
- FY2024US$19.9M
- FY2025US$1.6M
Operating profit
- FY2023−US$9.7M
- FY2024US$12.2M
- FY2025−US$5.3M
Net income
- FY2023−US$10.2M
- FY2024US$14.5M
- FY2025−US$7M
Key ratios (FY2025)
Why it matters
AprilBio was founded as a faculty-led spin-out from academia, a common origin for Korean biotech companies, and its pipeline is built around two proprietary platform technologies it developed in-house.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?